Skip to main content

Table 3 Comparison of insulin sensitivity and islet β-cell function

From: Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial

  Control Dapagliflozin 10 mg P-value
  Before After Con vs Bef Bef vs Aft
Stumvoll 1st phase index 1342.43 ± 585.89 − 1032.85 ± 1017.65 −  963.63 ± 928.78  < 0.001 0.775
Stumvoll 2nd phase index 367.02 ± 164.83 − 150.13 ± 223.52 − 144.11 ± 271.71 0.001 0.920
HOMA-β 115.06 ± 50.61 56.02 ± 26.08 59.85 ± 32.77 0.019 0.428
HOMA-IR 2.27 ± 1.24 4.52 ± 2.27 3.78 ± 1.59 0.044 0.624
QUICKI 0.35 ± 0.023 0.31 ± 0.02 0.32 ± 0.02 0.019 0.381
ISIstumvoll 0.078 ± 0.038 0.009 ± 0.017 0.027 ± 0.014 0.001 0.060
ISIMatsuda 119.35 ± 79.74 54.45 ± 25.11 76.95 ± 54.69 0.097 0.093
AUCGlu/Ins 0.20 ± 0.17 0.55 ± 0.49 1.00 ± 1.53 0.446 0.327
AUCIns 212.26 ± 175.00 145.76 ± 94.78 107.83 ± 66.60 0.402 0.069
  1. Con, control; Bef, before; Aft, after; AUCGlu, area under the curve of glucose; AUCIns, area under the curve of insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; QUICKI, quantitative insulin sensitivity check index; ISIstumvoll, insulin sensitivity index proposed by Stumvoll et al.; ISIMatsuda, insulin sensitivity index proposed by Matsuda et al.; 1st, first; 2nd, second